Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-1 in Castration Resistant Prostate Carcinoma
NCT04104607Phase 1Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2019
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CC-1 in prostate cancer (PCa), sponsored by University Hospital Tübingen. Primary endpoint: Incidence and severity of adverse events (AEs) at 21 days. Started Nov 2019; status: recruiting.
02
Drugs
CC-1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04104607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104607.